CVS Pharmacy, Inc. Regular Strength Aspirin Drug Facts | Aspirin
Aspirin 325 mg (NSAID)*
*nonsteroidal anti-inflammatory drug
Pain reliever/fever reducer
Reye’s syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye’s syndrome, a rare but serious illness.
Allergy alert: Aspirin may cause a severe allergic reaction which may include:
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you
if you have ever had an allergic reaction to any other pain reliever/fever reducer
taking a prescription drug for
These could be signs of a serious condition
ask a health professional before use. It is especially important not to use aspirin during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
corn starch, dibasic calcium phosphate dihydrate, hypromellose, talc, triacetin
1-800-719-9260
See New Warnings Information
Regular Strength
Aspirin
Fast, Safe Pain Relief
Pain Reliever/Fever Reducer (NSAID)
Headaches
Everyday Aches & Pains
325 mg
Compare to the active ingredient in Bayer®
Value Size {appears on 300 count and 500 count configurations only}
# Tablets {appears on 300 count and 500 count configurations only}


Manufacturer
CVS Pharmacy
Active Ingredients
Source
- U.S. National Library of Medicine
- DailyMed
- Last Updated: 4 May 2013
Drugs and Medications
Aspirin [Kareway Product, Inc.]
Drug Facts
Healthy accents aspirin [DZA Brands LLC]
DZA Brands, LLC Aspirin Drug Facts
Equaline aspirin [Supervalu Inc]
SuperValu Inc. Aspirin Drug Facts
Equaline aspirin [Supervalu Inc]
SuperValu Inc. Chewable Aspirin 81 mg Drug Facts
McKesson Aspirin Drug Facts
Clinical Trials
Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin
To determine the bioequivalence of new formula of aspirin relative to the established commercial effervescent aspirin when taken orally by healthy adult subjects
Pharmacokinetic Study Comparing Aspirin and Aspirin Granules
To determine the bioequivalence of new formula of aspirin relative to the established commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult subjects
The Effect of Serum LDL Lowering on Aspirin Resistance
Aspirin resistance is the persistent platelet activation, demonstrated by platelet function tests (1). The hypothesis is that:LDL lowering by statin in patients with aspirin resistance ca...
Aspirin Responsiveness in Women at Risk for Cardiac Events
The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be m...
Aspirin Resistance in Coronary Artery Disease
The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certa...
PubMed Articles
Can resistance to aspirin be reversed after an additional dose?
Aspirin resistance or aspirin non-responsiveness is a recently described phenomenon which has been consistently associated with an increased risk of cardiovascular events. This study was designed to d...
Aspirin resistance in patients with acute ischemic stroke.
Aspirin is used in ischemic stroke therapy. However, some patients are not responsive to the antithrombotic action of aspirin. The aim of this study was to assess the prevalence of aspirin resistance...
Aspirin for preventing venous thromboembolism.
To the Editor: In their report on the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trial, Brighton et al. (Nov. 22 issue)(1) describe a nonsignificant decrease in the rate of recurrent...
Aspirin for preventing venous thromboembolism.
To the Editor: In their report on the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trial, Brighton et al. (Nov. 22 issue)(1) describe a nonsignificant decrease in the rate of recurrent...
Aspirin for preventing venous thromboembolism.
To the Editor: In their report on the Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trial, Brighton et al. (Nov. 22 issue)(1) describe a nonsignificant decrease in the rate of recurrent...